SUBCUTANEOUS VS INTRAVENOUS ADMINISTRATION OF TRASTUZUMAB IN HER2+BREAST CANCER PATIENTS: A MACEDONIAN COST-MINIMIZATION ANALYSIS

被引：2
|
作者：
Nestorovska, A. [1 ]
Naumoska, Z. [1 ]
Grozdanova, A. [1 ]
Stoleski, D. [2 ]
Ivanovska, A. [2 ]
Risteski, M. [3 ]
Vasev, N. [3 ]
Ismaili, I. [3 ]
Stefanovski, P. [4 ]
Dimovski, A. [1 ]
Suturkova, L. [1 ]
Sterjev, Z. [5 ]
机构：
[1] ISPOR Republ Macedonia Reg Chapter, Skopje, Macedonia
[2] DOOEL, Roche Macedonia, Skopje, Macedonia
[3] Univ Clin Radiotherapy & Oncol, Skopje, Macedonia
[4] Clin Hosp, Bitola, Macedonia
[5] UKIM Skopje, Fac Pharm, Skopje, Macedonia
来源：
VALUE IN HEALTH | 2015年 / 18卷 / 07期
关键词：
D O I：
10.1016/j.jval.2015.09.1205
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN188
引用
收藏
页码：A463 / A463
页数：1
相关论文
共 50 条
  • [1] SUBCUTANEOUS VS INTRAVENOUS ADMINISTRATION OF TRASTUZUMAB IN HER2+BREAST CANCER PATIENTS: A MONTENEGRIN COST-MINIMIZATION ANALYSIS
    Todorovic, V
    Durutovic, I
    Ivanovska, A.
    Zajmovic, A.
    VALUE IN HEALTH, 2017, 20 (09) : A443 - A443
  • [2] Subcutaneous trastuzumab for the treatment of HER2+breast cancer in Canada: A cost-minimization study
    Coombes, Megan
    Yin, Lori
    Liu, Ingrid
    Shek, Norman
    Rusu, Flavia
    Mukherjee, Som
    CANCER RESEARCH, 2020, 80 (04)
  • [3] Cost-minimization analysis of subcutaneous versus intravenous trastuzumab administration in Chilean patients with HER2-positive early breast cancer
    Rojas, Luis
    Muniz, Sabrina
    Medina, Lidia
    Pena, Jose
    Acevedo, Francisco
    Pinto, Mauricio P.
    Sanchez, Cesar
    PLOS ONE, 2020, 15 (02):
  • [4] Cost-minimization analysis comparing subcutaneous trastuzumab at home with intravenous trastuzumab for HER2-positive breast cancer in Singapore
    Ouyang, Yanting
    Lee, Han Yi
    Leong, Fun Loon
    Tey, Han Jieh
    Shih, Vivianne
    Lim, Elaine Hsuen
    Graves, Nicholas
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2024, 16
  • [5] COST-MINIMIZATION ANALYSIS OF TRASTUZUMAB INTRAVENOUS VERSUS TRASTUZUMAB SUBCUTANEOUS FOR THE TREATMENT OF PATIENTS WITH HER2+EARLY BREAST CANCER AND METASTATIC BREAST CANCER IN GREECE
    Mylonas, C.
    Kourlaba, G.
    Fountzilas, G.
    Skroumpelos, A.
    Maniadakis, N.
    VALUE IN HEALTH, 2014, 17 (07) : A640 - A641
  • [6] COST-MINIMIZATION ANALYSIS OF TRASTUZUMAB INTRAVENOUS VERSUS TRASTUZUMAB SUBCUTANEOUS REGIMEN FOR BREAST CANCER MANAGEMENT IN HONG KONG
    Lee, V. W.
    Cheng, F.
    VALUE IN HEALTH, 2018, 21 : S16 - S16
  • [7] Cost Minimization Analysis of Intravenous or Subcutaneous Trastuzumab Treatment in Patients With HER2-Positive Breast Cancer in Ireland
    O'Brien, Gary L.
    O'Mahony, Cian
    Cooke, Katie
    Kinneally, Ada
    Sinnott, Sarah-Jo
    Walshe, Valerie
    Mulcahy, Mark
    Byrne, Stephen
    CLINICAL BREAST CANCER, 2019, 19 (03) : E440 - E451
  • [8] Cost minimization analysis of treatment with intravenous or subcutaneous trastuzumab in patients with HER2-positive breast cancer in Spain
    G. Lopez-Vivanco
    J. Salvador
    R. Diez
    D. López
    M. De Salas-Cansado
    B. Navarro
    J. De la Haba-Rodríguez
    Clinical and Translational Oncology, 2017, 19 : 1454 - 1461
  • [9] Cost minimization analysis of treatment with intravenous or subcutaneous trastuzumab in patients with HER2-positive breast cancer in Spain
    Lopez-Vivanco, G.
    Salvador, J.
    Diez, R.
    Lopez, D.
    De Salas-Cansado, M.
    Navarro, B.
    De la Haba-Rodriguez, J.
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2017, 19 (12): : 1454 - 1461
  • [10] Subcutaneous versus intravenous administration of trastuzumab: preference of HER2+breast cancer patients and financial impact of its use
    Lazaro Cebas, Andrea
    Cortijo Cascajares, Susana
    Pablos Bravo, Siria
    Goyache Goni, Maria Del Puy
    Gonzalez Monterrubio, Gema
    Perez Cardenas, Maria Dolores
    Ferrari Piquero, Jose Miguel
    JOURNAL OF BUON, 2017, 22 (02): : 334 - 339
12345